Bionano Genomics (BNGO) EPS (Weighted Average and Diluted) (2020 - 2026)

Bionano Genomics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.76 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.76, up 33.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.37 (up 91.97% YoY), and the FY2025 annual result was -$4.85, up 94.5% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.76 for Q1 2026 at Bionano Genomics, down from -$0.03 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q4 2025 to a low of -$402.75 in Q4 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$1.3 (2022), against an average of -$29.8.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 30880.77% in 2023 and soared 99.62% in 2025, its largest moves.
• Bionano Genomics' EPS (Weighted Average and Diluted) stood at -$1.3 in 2022, then slumped by 30880.77% to -$402.75 in 2023, then jumped by 98.03% to -$7.95 in 2024, then jumped by 99.62% to -$0.03 in 2025, then slumped by 2433.33% to -$0.76 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.76 (Q1 2026), -$0.03 (Q4 2025), and -$1.59 (Q3 2025), per Business Quant data.